Susan Haigney of PharmTech, a long-standing life sciences publication founded 1971 with a considerable readership spread across a variety of stakeholders in the sector, has published a deep article on Advancements in Biopharma Spur Innovation, referencing industry KOL quotes including Max Baumann, Partner at Treehill Partners:
- “As we observed in an industry analysis we performed comprising 1200 clinical programs, only a minority of companies currently optimize pharmaceutical product development for commercial success. Combined with increased segmentation of clinical end markets, this has a significant impact on the financial return potential which pharmaceutical drug development offers to investors, and absent a clear investment thesis, not all the products we currently see in development will be successful in securing funding to market entry and break-even.
- There is significant value to be generated in two main areas, namely, ‘doing the right thing‘/development strategy — where AI/ML can be instrumental in identifying and supporting the best strategic direction and avoid mis-steps that may put an entire company on an inferior path — and ‘doing things the right way’/execution of key tasks along the development journey, where error rates can be reduced, equations be better solved, and ultimately better development outcomes be created through aggregating thousands of slightly improved puzzle pieces.
- The interplay between modality innovation and manufacturing evolution will define the next decade of biopharma, driving both operational excellence and improved patient outcomes. We remain cautious about the current geopolitical environment inflicting fundamental changes to our industry, which range from choice of production location to pricing of the end product and with that affect the commercial attractiveness/viability of geographical markets across the globe.”
Read the full article at PharmTech.